
Melanie R Nicol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/245622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 2020, 383, 517-525.	13.9	1,081
2	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 2020, 173, 623-631.	2.0	444
3	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 2020, 7, ofaa130.	0.4	160
4	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	2.9	103
5	Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infectious Diseases, The, 2019, 19, 843-851.	4.6	92
6	Pharmacogenomics of COVID-19 therapies. Npj Genomic Medicine, 2020, 5, 35.	1.7	63
7	RGS inhibition at Cα _{i2} selectively potentiates 5-HT1A–mediated antidepressant effects. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11086-11091.	3.3	60
8	Finding the Dose for Hydroxychloroquine Prophylaxis for COVIDâ€19: The Desperate Search for Effectiveness. Clinical Pharmacology and Therapeutics, 2020, 108, 766-769.	2.3	46
9	Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. Journal of Clinical Pharmacology, 2014, 54, 574-583.	1.0	42
10	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa500.	0.4	38
11	Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	35
12	Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. Clinical Pharmacokinetics, 2012, 51, 809-822.	1.6	30
13	Pharmacologic Opportunities for HIV Prevention. Clinical Pharmacology and Therapeutics, 2010, 88, 598-609.	2.3	28
14	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVIDâ€19 Infection. Clinical Pharmacology and Therapeutics, 2020, 108, 1135-1149.	2.3	25
15	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19—A Call for Clinical Trials. Open Forum Infectious Diseases, 2020, 7, ofaa350.	0.4	25
16	Review of Realâ€World Implementation Data on Emtricitabineâ€Tenofovir Disoproxil Fumarate as HIV Preâ€exposure Prophylaxis in the United States. Pharmacotherapy, 2019, 39, 486-500.	1.2	19
17	Models for Predicting Effective HIV Chemoprevention in Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 369-376.	0.9	17
18	Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model. Open Forum Infectious Diseases, 2019, 6, .	0.4	17

MELANIE R NICOL

#	Article	IF	CITATIONS
19	HIV pre-exposure prophylaxis trials: the road to success. Clinical Investigation, 2013, 3, 295-308.	0.0	16
20	Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. Open Forum Infectious Diseases, 2019, 6, ofz478.	0.4	15
21	Short Communication: Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. AIDS Research and Human Retroviruses, 2014, 30, 1058-1064.	0.5	14
22	Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. Journal of Clinical Pharmacology, 2018, 58, 1381-1395.	1.0	14
23	Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis. Clinical Infectious Diseases, 2020, 70, 1717-1724.	2.9	10
24	The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. Aids, 2018, 32, 11-15.	1.0	8
25	Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis. Clinical and Translational Science, 2019, 12, 445-449.	1.5	7
26	Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda. BMC Infectious Diseases, 2020, 20, 572.	1.3	7
27	Treating viruses in the brain: Perspectives from NeuroAIDS. Neuroscience Letters, 2021, 748, 135691.	1.0	7
28	Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 565-576.	0.8	3
29	Endogenous Hormones and Antiretroviral Exposure in Plasma, Cervicovaginal Fluid, and Upper-Layer Packed Cells of Malawian Women Living with HIV. AIDS Research and Human Retroviruses, 2020, 36, 641-646.	0.5	2
30	The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations. Clinical Pharmacology and Therapeutics, 2021, 109, 793-796.	2.3	2
31	Reply to Neves. Clinical Infectious Diseases, 2021, 73, e1772-e1774.	2.9	2
32	A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. AIDS Research and Human Retroviruses, 2021, 37, 529-533.	0.5	1
33	Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda. Wellcome Open Research, 0, 6, 302.	0.9	1
34	Oral Maraviroc and Tenofovir for HIV Prevention in Women: An <i>Ex Vivo</i> and Translational Approach. AIDS Research and Human Retroviruses, 2014, 30, A58-A58.	0.5	0
35	Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. Wellcome Open Research, 2018, 3, 111.	0.9	0
36	88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents. Journal of Clinical and Translational Science, 2021, 5, 96-96.	0.3	0

#	Article	IF	CITATIONS
37	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. Open Forum Infectious Diseases, 0, , .	0.4	0
38	Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. Wellcome Open Research, 2018, 3, 111.	0.9	0
39	Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda. Wellcome Open Research, 2021, 6, 302.	0.9	ο